Medical service package and expenditure analysis of multi-drug resistant tuberculosis
CHEN Cheng, LI Ren-zhong, RUAN Yun-zhou, ZHU Li-zhen, TU De-hua, ZHAO Jin, CHEN Ming-ting, WANG Li-xia
Department of Drug Resistant Tuberculosis, National Center for TB Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206,China
CHEN Cheng, LI Ren-zhong, RUAN Yun-zhou, ZHU Li-zhen, TU De-hua, ZHAO Jin, CHEN Ming-ting, WANG Li-xia. Medical service package and expenditure analysis of multi-drug resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2013, 35(5): 352-356.
[1]Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med, 2012,366(23):2161-2170.[2]World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update 2008. WHO/HTM/TB/2008.402. Geneva: World Health Organization, 2008.[3]王宇.耐多药肺结核防治管理工作方案.北京:军事医学科学出版社,2012.[4]刘金玲,姜丽萍,李伟,等. 53例耐多药肺结核患者抗结核药物不良反应发生情况及处理. 当代医学,2012,18(2):75-76.[5]Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.Int J Tuberc Lung Dis,2004,8(11):1382-1384.[6]Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis,2001,5(7):648-655.